Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 August 2021 | Story ANDRÉ DAMONS | Photo ANDRÉ DAMONS
Dr Osayande Evbuomwan, a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, always wanted to specialise in an area of medicine that was novel, innovative, intriguing and involved a lot of opportunities for groundbreaking research

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS) always wanted to specialize in an area of medicine that was novel, innovative, intriguing and involved many opportunities for groundbreaking research.

This passionate medical man, who joined the UFS in 2019, is behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer. 
The UFS and the Free State province can now join other South African universities, like the University of Pretoria, University of the Witwatersrand, and other provinces in using this method to treat MCRPC patients. 

Built for this job

Dr Evbuomwan explains nuclear medicine is a medical specialty that involves the use of unsealed sources of radiation in the form of radioisotopes for the diagnosis and treatment of various disease conditions including cancers.
“It’s novelty and opportunity for research and ability to diagnose and treat disease conditions in one specialty attracted me to this field. I always wanted to be a doctor. I see it as a calling. It was also something my mum discovered while I was growing up as a child. In my next life, I would choose to be a medical doctor again,” he says.

“I was built for this job and it is always my joy to have the opportunity to carry out my work. We have been well-trained for this; we support all our skills with prayers. We try to give our patients the very best,” says Dr Evbuomwan, who is originally from Benin City, Edo state, Nigeria. 

After graduating as a nuclear medicine specialist from Wits University, Dr Evbuomwan moved to the City of Roses after a work opportunity opened. He saw it as an opportunity to showcase his talents.

“I have been privileged to receive training in this treatment during my residency training at Wits. I treated a few of these patients during my training and the results were amazing. The University of Pretoria has also been involved with this treatment, with some amazing results that are recognised worldwide. 

“This was enough to convince me to push for our department to also join the powerhouses and offer this treatment to patients who need it. With the influence of a very understanding head of department, Dr Gerrit Engelbrecht, we have been successful in pushing for the commencement of this treatment at our facility,” says Dr Evbuomwan.

Important treatment
According to him, the availability and expertise of Lutetium 177 PSMA (Lu-177 PSMA) therapy to treat MCRPC is very important for the Free State and the UFS, as it is able to offer an option for patients who do not qualify for available conventional treatment and/or who have failed the first line of conventional treatment. 

“In the majority of patients this treatment offers improved quality of life, disease-free progression and improved overall survival. It also alleviates the constant bone pains these patients have to go through daily. To be able to offer this treatment puts the university and the province on the map alongside other top institutions in and outside the country. It also offers opportunity for research,” says Dr Evbuomwan.

He believes with a PET/CT camera for proper staging of these patients with cancer the UFS would be able to expand the treatment of patients suffering from this deadly illness. Currently the university does not possess such a camera and has to use lesser methods in identifying the right patients for this therapy.

News Archive

UFS leads the way with GMO testing
2003-08-25

A formal agreement linking Africa’s first testing facility for genetically modified organisms (GMO) to an international organization was signed at the University of the Free State.

According to the manager of the GMO testing facility, Dr Chris Viljoen of the Department of Plant Sciences, the facility is now part of GeneScan, a world leader in food diagnostic testing, which has its headquarters in Germany with subsidiaries in the Unites States, Brazil and Hong Kong.

The facility at the UFS has been selected by the second largest international food company to do all its South African GMO testing for export products.

The GMO testing facility is the brainchild of Dr Viljoen, who is a specialist in the field of marker biotechnology and its applications in crop science.

He says the need for such a testing facility arose due to the international regulations on GMOs in food, especially Europe and Asia that requires South African exporters to certify whether their products contain any GMO.

“The regulations in Europe and Asia reflect a consumer need for choice in what they eat due to concerns over the safety of GMOs, as well as environmental and ethical issues. GMO testing and labelling allow consumers the right of choice to eat genetically modified foods or not. According to EU regulations, any product with a GMO content of 1% or higher is labelled as containing GMO.”

According to Dr Viljoen only four products in South Africa are currently GMO. They are white and yellow maize that have been made insect resistant, soya bean that is herbicide tolerant and insect resistant cotton. He says that the awareness of GMOs among South Africans is still very limited, especially in poorer communities, but it is likely to increase with the efforts being made in consumer education by government, seed companies and NGOs.

The testing facility has been established to accommodate the local as well as international market. The GMO testing at the UFS facility is performed using real time PCR, the most advanced means of GMO detection currently available, and using GeneScan developed technology that is recognized worldwide.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept